NASDAQ:KPTI Karyopharm Therapeutics (KPTI) Stock Forecast, Price & News $2.32 -0.09 (-3.73%) (As of 05/26/2023 ET) Add Compare Share Share Today's Range$2.32▼$2.4650-Day Range$2.32▼$4.5952-Week Range$2.28▼$6.84Volume1.51 million shsAverage Volume2.95 million shsMarket Capitalization$264.50 millionP/E RatioN/ADividend YieldN/APrice Target$8.00 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Karyopharm Therapeutics MarketRank™ ForecastAnalyst RatingModerate Buy2.71 Rating ScoreUpside/Downside244.8% Upside$8.00 Price TargetShort InterestBearish15.02% of Shares Sold ShortDividend StrengthN/ASustainability-1.11Upright™ Environmental ScoreNews Sentiment0.74Based on 3 Articles This WeekInsider TradingSelling Shares$252,484 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.24) to ($1.02) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.19 out of 5 starsMedical Sector422nd out of 1,012 stocksPharmaceutical Preparations Industry194th out of 495 stocks 3.4 Analyst's Opinion Consensus RatingKaryopharm Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.71, and is based on 5 buy ratings, 2 hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $8.00, Karyopharm Therapeutics has a forecasted upside of 244.8% from its current price of $2.32.Amount of Analyst CoverageKaryopharm Therapeutics has only been the subject of 1 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted15.02% of the outstanding shares of Karyopharm Therapeutics have been sold short.Short Interest Ratio / Days to CoverKaryopharm Therapeutics has a short interest ratio ("days to cover") of 6.6.Change versus previous monthShort interest in Karyopharm Therapeutics has recently decreased by 4.68%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldKaryopharm Therapeutics does not currently pay a dividend.Dividend GrowthKaryopharm Therapeutics does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreKaryopharm Therapeutics has received a 71.09% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Other cancer medication", "Clinical research services for physical health", and "Basic medical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Karyopharm Therapeutics is -1.11. Previous Next 1.5 News and Social Media Coverage News SentimentKaryopharm Therapeutics has a news sentiment score of 0.74. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Karyopharm Therapeutics this week, compared to 3 articles on an average week.Search InterestOnly 25 people have searched for KPTI on MarketBeat in the last 30 days. This is a decrease of -39% compared to the previous 30 days.MarketBeat FollowsOnly 5 people have added Karyopharm Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Karyopharm Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $252,484.00 in company stock.Percentage Held by InsidersOnly 3.32% of the stock of Karyopharm Therapeutics is held by insiders.Percentage Held by Institutions96.13% of the stock of Karyopharm Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Karyopharm Therapeutics are expected to grow in the coming year, from ($1.24) to ($1.02) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Karyopharm Therapeutics is -1.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Karyopharm Therapeutics is -1.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Previous Next See Top Rated MarketRank™ Stocks Here About Karyopharm Therapeutics (NASDAQ:KPTI) StockKaryopharm Therapeutics, Inc. is a commercial-stage pharmaceutical company, which engages in the discovery, development, and commercialization of drugs directed against nuclear export for the treatment of cancer and other diseases. Its Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Karyopharm's compound, XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. In addition to single-agent and combination activity against a variety of human cancers, SINE compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses, and wound-healing. Karyopharm has several investigational programs in clinical or preclinical development.Read More Receive KPTI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Karyopharm Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address KPTI Stock News HeadlinesMay 23, 2023 | finance.yahoo.comKaryopharm to Present New Selinexor Data at the 2023 American Society of Clinical Oncology and European Hematology Association Annual MeetingsMay 18, 2023 | msn.comKaryopharm Therapeutics's Return On Capital Employed InsightsMay 28, 2023 | Stocks To Trade (Ad)15 A.I. Trading Opportunities a DayUsing our algorithm, we sift through 15,000 stocks every second. We generate 15 trading opportunities a day.May 12, 2023 | americanbankingnews.comKaryopharm Therapeutics Inc. (NASDAQ:KPTI) Given Average Recommendation of "Moderate Buy" by BrokeragesMay 9, 2023 | finance.yahoo.comKaryopharm Therapeutics Inc. (NASDAQ:KPTI) Q1 2023 Earnings Call TranscriptMay 9, 2023 | americanbankingnews.comWedbush Weighs in on Karyopharm Therapeutics Inc.'s FY2027 Earnings (NASDAQ:KPTI)May 7, 2023 | americanbankingnews.comKaryopharm Therapeutics (NASDAQ:KPTI) Price Target Cut to $10.00 by Analysts at Robert W. BairdMay 6, 2023 | msn.comBaird Maintains Karyopharm Therapeutics (KPTI) Outperform RecommendationMay 28, 2023 | Stocks To Trade (Ad)15 A.I. Trading Opportunities a DayUsing our algorithm, we sift through 15,000 stocks every second. We generate 15 trading opportunities a day.May 5, 2023 | finanznachrichten.deKaryopharm Therapeutics Inc.: Karyopharm Reports First Quarter 2023 Financial Results and Highlights Recent Company ProgressMay 5, 2023 | msn.comHC Wainwright & Co. Maintains Karyopharm Therapeutics (KPTI) Buy RecommendationMay 5, 2023 | msn.comRBC Capital Maintains Karyopharm Therapeutics (KPTI) Outperform RecommendationMay 5, 2023 | finance.yahoo.comKaryopharm Therapeutics First Quarter 2023 Earnings: Beats ExpectationsMay 5, 2023 | americanbankingnews.comHC Wainwright Lowers Karyopharm Therapeutics (NASDAQ:KPTI) Price Target to $10.00May 4, 2023 | finance.yahoo.comWhy Karyopharm Therapeutics Shares Slumped ThursdayMay 4, 2023 | msn.comKaryopharm hits four-month low after guidance cutMay 4, 2023 | finance.yahoo.comKaryopharm Therapeutics (KPTI) Q1 2023 Earnings Call TranscriptMay 4, 2023 | finance.yahoo.comKaryopharm Reports First Quarter 2023 Financial Results and Highlights Recent Company ProgressMay 3, 2023 | finance.yahoo.comKaryopharm Announces Presentation of Interim Data from Phase 2 Study of Single-Agent Eltanexor in Relapsed/Refractory (R/R) Higher-Risk Myelodysplastic Neoplasms (MDS) at 17th International Congress on MDSApril 27, 2023 | finance.yahoo.comWill Karyopharm Therapeutics (KPTI) Report Negative Q1 Earnings? What You Should KnowApril 26, 2023 | americanbankingnews.comReshma Rangwala Sells 6,770 Shares of Karyopharm Therapeutics Inc. (NASDAQ:KPTI) StockApril 23, 2023 | americanbankingnews.comKaryopharm Therapeutics (NASDAQ:KPTI) Given "Buy" Rating at HC WainwrightApril 23, 2023 | americanbankingnews.comBrokers Offer Predictions for Karyopharm Therapeutics Inc.'s FY2023 Earnings (NASDAQ:KPTI)April 23, 2023 | americanbankingnews.comKaryopharm Therapeutics Inc. (NASDAQ:KPTI) to Post Q1 2023 Earnings of ($0.34) Per Share, Wedbush ForecastsApril 21, 2023 | markets.businessinsider.comSVB Securities Reaffirms Their Hold Rating on Karyopharm Therapeutics (KPTI)April 21, 2023 | americanbankingnews.comQ1 2023 EPS Estimates for Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Decreased by HC WainwrightApril 19, 2023 | msn.comHC Wainwright & Co. Reiterates Karyopharm Therapeutics (KPTI) Buy RecommendationSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive KPTI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Karyopharm Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address KPTI Company Calendar Last Earnings11/03/2021Today5/28/2023Next Earnings (Estimated)8/03/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:KPTI CUSIPN/A CIK1503802 Webwww.karyopharm.com Phone(617) 658-0600FaxN/AEmployees442Year FoundedN/APrice Target and Rating Average Stock Price Forecast$8.00 High Stock Price Forecast$10.00 Low Stock Price Forecast$5.00 Forecasted Upside/Downside+244.8%Consensus RatingModerate Buy Rating Score (0-4)2.71 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($1.80) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-165,290,000.00 Net Margins-106.69% Pretax Margin-106.50% Return on EquityN/A Return on Assets-53.95% Debt Debt-to-Equity RatioN/A Current Ratio5.17 Quick Ratio5.11 Sales & Book Value Annual Sales$157.07 million Price / Sales1.68 Cash FlowN/A Price / Cash FlowN/A Book Value($0.40) per share Price / Book-5.80Miscellaneous Outstanding Shares114,010,000Free Float110,225,000Market Cap$264.50 million OptionableOptionable Beta0.07 Key ExecutivesRichard A. PaulsonPresident, CEO & Non-Executive DirectorSharon ShachamScientific Advisory BoardMike MasonChief Financial Officer, Treasurer & EVPReshma RangwalaChief Medical OfficerAmama SadiqSenior VP-Global Medical & Scientific AffairsKey CompetitorsInozyme PharmaNASDAQ:INZYSavaraNASDAQ:SVRAFoghorn TherapeuticsNASDAQ:FHTXReneo PharmaceuticalsNASDAQ:RPHMNGM BiopharmaceuticalsNASDAQ:NGMView All CompetitorsInsiders & InstitutionsAmeriprise Financial Inc.Bought 92,867 shares on 5/22/2023Ownership: 0.226%Putnam Investments LLCSold 121,852 shares on 5/22/2023Ownership: 0.106%New York State Common Retirement FundSold 30,000 shares on 5/18/2023Ownership: 0.017%AQR Capital Management LLCBought 18,866 shares on 5/16/2023Ownership: 0.071%Jane Street Group LLCBought 11,400 shares on 5/16/2023Ownership: 0.000%View All Insider TransactionsView All Institutional Transactions KPTI Stock - Frequently Asked Questions Should I buy or sell Karyopharm Therapeutics stock right now? 7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Karyopharm Therapeutics in the last twelve months. There are currently 2 hold ratings and 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" KPTI shares. View KPTI analyst ratings or view top-rated stocks. What is Karyopharm Therapeutics' stock price forecast for 2023? 7 Wall Street analysts have issued 1 year price objectives for Karyopharm Therapeutics' stock. Their KPTI share price forecasts range from $5.00 to $10.00. On average, they anticipate the company's share price to reach $8.00 in the next twelve months. This suggests a possible upside of 244.8% from the stock's current price. View analysts price targets for KPTI or view top-rated stocks among Wall Street analysts. How have KPTI shares performed in 2023? Karyopharm Therapeutics' stock was trading at $3.40 at the beginning of 2023. Since then, KPTI stock has decreased by 31.8% and is now trading at $2.32. View the best growth stocks for 2023 here. When is Karyopharm Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 3rd 2023. View our KPTI earnings forecast. How were Karyopharm Therapeutics' earnings last quarter? Karyopharm Therapeutics Inc. (NASDAQ:KPTI) issued its quarterly earnings results on Wednesday, November, 3rd. The company reported ($0.69) earnings per share for the quarter, missing analysts' consensus estimates of ($0.68) by $0.01. The company earned $37.69 million during the quarter, compared to analysts' expectations of $25.84 million. During the same quarter last year, the firm earned ($0.73) earnings per share. What ETFs hold Karyopharm Therapeutics' stock? ETFs with the largest weight of Karyopharm Therapeutics (NASDAQ:KPTI) stock in their portfolio include Invesco Nasdaq Future Gen 200 ETF (QQQS), iShares Genomics Immunology and Healthcare ETF (IDNA), SPDR S&P Biotech ETF (XBI), Direxion Daily S&P Biotech Bull 3x Shares (LABU), Invesco Nasdaq Biotechnology ETF (IBBQ), iShares Biotechnology ETF (IBB), What guidance has Karyopharm Therapeutics issued on next quarter's earnings? Karyopharm Therapeutics updated its FY 2023 earnings guidance on Thursday, May, 4th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $145.00 million-$160.00 million, compared to the consensus revenue estimate of $157.37 million. What is Michael Kauffman's approval rating as Karyopharm Therapeutics' CEO? 31 employees have rated Karyopharm Therapeutics Chief Executive Officer Michael Kauffman on Glassdoor.com. Michael Kauffman has an approval rating of 83% among the company's employees. What other stocks do shareholders of Karyopharm Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Karyopharm Therapeutics investors own include NVIDIA (NVDA), Gilead Sciences (GILD), CRISPR Therapeutics (CRSP), Alibaba Group (BABA), Micron Technology (MU), Invitae (NVTA), Advanced Micro Devices (AMD), AbbVie (ABBV), Inovio Pharmaceuticals (INO) and Bristol-Myers Squibb (BMY). What is Karyopharm Therapeutics' stock symbol? Karyopharm Therapeutics trades on the NASDAQ under the ticker symbol "KPTI." Who are Karyopharm Therapeutics' major shareholders? Karyopharm Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include State Street Corp (8.93%), BlackRock Inc. (7.96%), Palo Alto Investors LP (4.98%), Rubric Capital Management LP (3.90%), Barclays PLC (2.50%) and Bank of America Corp DE (1.89%). Insiders that own company stock include Christopher Brett Primiano, Deepika Pakianathan, Garen G Bohlin, Jatin Shah, John Demaree, Mansoor Raza Mirza, Michael Kauffman, Michael Mason, Reshma Rangwala, Richard A Paulson, Sharon Shacham, Sohanya Roshan Cheng, Stephen Mitchener, Stuart Poulton and Tanya Lewis. View institutional ownership trends. How do I buy shares of Karyopharm Therapeutics? Shares of KPTI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Karyopharm Therapeutics' stock price today? One share of KPTI stock can currently be purchased for approximately $2.32. How much money does Karyopharm Therapeutics make? Karyopharm Therapeutics (NASDAQ:KPTI) has a market capitalization of $264.50 million and generates $157.07 million in revenue each year. The company earns $-165,290,000.00 in net income (profit) each year or ($1.80) on an earnings per share basis. How many employees does Karyopharm Therapeutics have? The company employs 442 workers across the globe. How can I contact Karyopharm Therapeutics? Karyopharm Therapeutics' mailing address is 85 WELLS AVENUE SECOND FLOOR, NEWTON MA, 02459. The official website for the company is www.karyopharm.com. The company can be reached via phone at (617) 658-0600 or via email at ikarp@karyopharm.com. This page (NASDAQ:KPTI) was last updated on 5/28/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Karyopharm Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.